Kim Linton

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · The Lancet Haematology · 2016 · 582 citations · Full text

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · The Lancet Haematology · 2017 · 364 citations · Full text

Neuro-oncology, Radiation Oncology, Lymphoid Neoplasia +12

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings, Rogier Mous, Michael Roost Clausen et al. · The Lancet · 2021 · 315 citations · Full text

Subcutaneous Epcoritamab, Lymphoid Neoplasia, Dose Escalation +4

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

M. Dreyling, Franck Morschhauser, Krimo Bouabdallah et al. · Annals of Oncology · 2017 · 267 citations · Full text

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Myron S. Czuczman, Marek Trněný, Andrew Davies et al. · Clinical Cancer Research · 2017 · 164 citations · Full text